Ardelyx Inc (ARDX)

Currency in USD
3.090
-0.030(-0.96%)
Closed·
3.110+0.020(+0.65%)
·
ARDX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.0503.150
52 wk Range
2.8008.400
Key Statistics
Prev. Close
3.12
Open
3.14
Day's Range
3.05-3.15
52 wk Range
2.8-8.4
Volume
2.38M
Average Volume (3m)
4.39M
1-Year Change
-47.2696%
Book Value / Share
0,66
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ARDX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.500
Upside
+304.53%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts do not anticipate the company will be profitable this year

Ardelyx Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy

Analyst Ratings

11 Buy
0 Hold
0 Sell
Ratings:
11 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.500
(+304.53% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy15.00+385.44%16.00MaintainAug 17, 2026
TD Cowen
Buy10.00+223.62%13.00MaintainAug 07, 2026
Ladenburg Thalmann
Buy16.00+417.80%-New CoverageJun 16, 2026
Leerink Partners
Buy17.00+450.16%-MaintainMar 12, 2026
Piper Sandler
Buy16.00+417.80%-MaintainFeb 23, 2026

Ardelyx Inc Earnings Call Summary for Q3/2026

  • Q3 revenue rose 19% YoY to $125.5M, missing $129.22M forecast; net loss narrowed to $700K from $1M, driving shares up 9.57% after-hours.
  • IBSRELA led growth with $96.3M revenue (up 23% YoY); XPHOZAH contributed $29.2M (up 7%), supported by expanded sales force and new DTC campaign.
  • Company reaffirmed 2026 guidance: IBSRELA revenue $350-370M, XPHOZAH $110-120M, operating expenses below $500M, targeting 2027 profitability.
  • ACCEL Phase III trial for IBSRELA in chronic constipation completed enrollment ahead of schedule; topline results expected H2 2027.
  • Key risks include rising gross-to-net erosion (31.7%), prior authorization barriers, dialysis reimbursement uncertainty, and increased R&D/SG&A spending.
Last Updated: 2026/11/04, 00:12
Read Full Transcript

Earnings

Latest Release
Nov 03, 2026
EPS / Forecast
-- / -0,01
Revenue / Forecast
125,45M / 129,22M
EPS Revisions
Last 90 days

ARDX Income Statement

Compare ARDX to Peers and Sector

Metrics to compare
ARDX
Peers
Sector
Relationship
P/E Ratio
−14.0x−2.6x−0.2x
PEG Ratio
−2.91−0.040.00
Price/Book
4.7x1.9x2.6x
Price / LTM Sales
1.7x1.7x2.8x
Upside (Analyst Target)
304.5%45.0%65.0%
Fair Value Upside
Unlock12.6%9.6%Unlock

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
77,57M30,86%239,70M
Other Institutional Investors
118,84M47,28%367,22M
Public Companies & Retail Investors
54,96M21,86%169,82M
Total
251,37M100,00%776,74M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9,35%23 504 63072 629
Integrated Core Strategies (US) LLC7,05%17 721 73254 760

FAQ

What Is the Ardelyx Inc (ARDX) Stock Price Today?

The Ardelyx Inc stock price today is 3,090 USD.

What Stock Exchange Does Ardelyx Inc Trade On?

Ardelyx Inc is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Ardelyx Inc?

The stock symbol for Ardelyx Inc is "ARDX."

What Is the Ardelyx Inc Market Cap?

As of today, Ardelyx Inc market cap is 784,280M USD.

What Is Ardelyx Inc's Earnings Per Share (TTM)?

The Ardelyx Inc EPS (TTM) is -0,22.

When Is the Next Ardelyx Inc Earnings Date?

Ardelyx Inc will release its next earnings report on Feb 25, 2027.

From a Technical Analysis Perspective, Is ARDX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Ardelyx Inc Stock Split?

Ardelyx Inc has split 0 times.

How Many Employees Does Ardelyx Inc Have?

Ardelyx Inc has 489 employees.

What is the current trading status of Ardelyx Inc (ARDX)?

As of Nov 14, 2026, Ardelyx Inc (ARDX) is trading at a price of 3,090 USD, with a previous close of 3,120 USD. The stock has fluctuated within a day range of 3,050 USD to 3,150 USD, while its 52-week range spans from 2,800 USD to 8,400 USD.

What Is Ardelyx Inc (ARDX) Price Target According to Analysts?

The average 12-month price target for Ardelyx Inc is 12,500 USD, with a high estimate of 18 USD and a low estimate of 8 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +304,53% Upside potential.

What Is the ARDX Premarket Price?

ARDX's last pre-market stock price is 3,110 USD. The pre-market share volume is 4 960,000, and the stock has decreased by -0,010, or -0,320%.

What Is the ARDX After Hours Price?

ARDX's last after hours stock price is 3,110 USD, the stock has decreased by 0,020, or 0,650%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.